<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 20%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):<B>
September 10, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ALBANY MOLECULAR RESEARCH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 32%; vertical-align: bottom; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 2%; vertical-align: top; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: bottom; font-weight: bold; text-align: center">000-25323</TD>
    <TD STYLE="width: 2%; vertical-align: top; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: bottom; font-weight: bold; text-align: center">14-1742717</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">(State or other jurisdiction</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">(Commission</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">(IRS Employer</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">of incorporation)</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">File Number)</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48%; vertical-align: bottom; font-weight: bold; text-align: center">21 Corporate Circle, P.O. Box 15098, Albany, NY</TD>
    <TD STYLE="width: 4%; vertical-align: top; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; vertical-align: top; font-weight: bold; text-align: center">12212</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(518) 512-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Former name or former address, if
changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2. below) :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-weight: bold">Item 5.02.</TD>
    <TD STYLE="width: 90%; font-weight: bold">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 12, 2012,
Albany Molecular Research, Inc. (the &ldquo;<U>Company</U>&rdquo;) issued a press release (the &ldquo;<U>Press Release</U>&rdquo;)
announcing that Mr. Michael Nolan has been appointed by the Board of Directors as the Vice President, Chief Financial Officer and
Treasurer of the Company, such appointment to be effective on September 17, 2012.&nbsp;&nbsp;Mr. Nolan will enter into an Employment
Agreement with the Company effective September 17, 2012 (the &ldquo;<U>Employment Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Mr. Nolan, 46, was most recently Vice President
Finance, Financial Planning and Analysis at the Delaware North Companies, headquartered in Buffalo, New York. Prior to that, Mr.
Nolan spent three years, from 2009 through 2012, at Thermo Fisher Scientific, Inc. in the role of Vice President, Finance, Analytical
Instruments Group where he was responsible for the global financial operations of a portfolio with revenue of $3 billion operating
across 3 divisions with 15 business units, 41 plant sites and 9,700 employees. Prior to Thermo Fisher Scientific, from 2004 through
2009, Mr. Nolan held positions of increasing responsibility at ALCAN, which was later acquired by Rio Tinto plc. Most recently,
while at Rio Tinto plc, Mr. Nolan was accountable for leading the integration of 13 global ALCAN and Rio Tinto plc functions, including
legal, company secretarial, business development and all finance functions including both the corporate and business teams. Mr.
Nolan began his career in 1989 at E.I. du Pont de Nemours Company and received his MBA from The University of Windsor and a B.A.
in Economics from The University of Western Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Nolan will report
to the Chairman, President and Chief Executive Officer of AMRI. Mr. Nolan will receive a base salary of $370,000 per year and is
eligible for a cash bonus of up to 67.5% of his base salary, which would be paid with respect to any fiscal year based on the performance
of the Company to established objectives, along with the achievement of personal goals set for Mr. Nolan. In addition, Mr. Nolan
will be paid a signing bonus of approximately $31,000 at the time of employment and will be eligible for the Company&rsquo;s standard
relocation package for senior executive officers. In the event that Mr. Nolan terminates his employment with AMRI within 24 months
he will be required to repay the signing bonus and any relocation fees actually incurred. Effective on the date of employment Mr.
Nolan will be granted non-qualified stock options to purchase 100,000 shares of the Company&rsquo;s common stock and 50,000 shares
of restricted stock. The stock options will be granted at the fair market value on the date of grant and the shares of restricted
stock and the stock options will vest 25% per year on each anniversary of the date of grant. The Employment Agreement is expected
to contain terms and conditions regarding restrictive covenants; termination; change of control; and other matters similar to those
found in the employment agreements currently in place between the Company and its other senior executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Press Release also
announced that Mr. Mark T. Frost, the Senior Vice President of Finance and Administration, Chief Financial Officer and Treasurer
of the Company, will be terminating employment with the Company on September 14, 2012.&nbsp;&nbsp;Mr. Frost has entered into a
Separation Agreement with the Company effective September 10, 2012 (the &ldquo;<U>Separation Agreement</U>&rdquo;), which provides
that Mr. Frost&rsquo;s last day of employment with the Company will be September 14, 2012 (the &ldquo;<U>Termination Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Separation Agreement
provides for the payment of certain severance benefits to Mr. Frost following the Termination Date and the continuation of certain
obligations under the terms of the Amended and Restated Employment Agreement between the Company and Mr. Frost dated as of April
5, 2012.&nbsp;&nbsp;The severance benefits include the following: (a) base salary and health and dental benefit continuation through
December 31, 2013; (b) certain bonus payments related to the Company&rsquo;s fiscal 2012 year, which will be payable only after
the completion of the fiscal year and a portion of which is dependent on the Company meeting its performance goals for such fiscal
year, (c) payment of certain outplacement expenses and (d) vesting of certain outstanding restricted stock awards held by Mr. Frost
immediately prior to the Termination Date that vest over time and have not vested.&nbsp;&nbsp;Mr. Frost will receive his regular
rate of salary through the Termination Date.&nbsp;&nbsp;In addition, the Separation Agreement includes a mutual general release
of claims between Mr. Frost and the Company arising out of or related to Mr. Frost&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description of
the Separation Agreement and the Employment Agreement contained herein do not purport to be complete and are qualified in the entirety
by reference to the complete text of the Separation Agreement and the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release announcing these
events is attached hereto as Exhibit 99.1 and is furnished herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-weight: bold">Item 9.01.</TD>
    <TD STYLE="width: 90%; font-weight: bold">Financial Statements and Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-decoration: none; width: 10%">Exhibit No.</TD>
    <TD NOWRAP STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 88%; font-weight: bold; text-decoration: none; border-bottom: Black 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated September 12, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Date: September 13, 2012</TD>
    <TD COLSPAN="2">ALBANY MOLECULAR RESEARCH, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Lori M. Henderson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Lori M. Henderson</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:&nbsp; Vice President and General Counsel</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none; width: 10%">Exhibit</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none; border-bottom: Black 1pt solid">No.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Description&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated September 12, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v323588_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 20994}]
{"company-data": {"conformed-name": "ALBANY MOLECULAR RESEARCH INC", "cik": "0001065087", "assigned-sic": "8731", "irs-number": "141742717", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35622", "film-number": "121090339"}, "business-address": {"street1": "21 CORPORATE CIRCLE", "street2": "P O BOX 15098", "city": "ALBANY", "state": "NY", "zip": "12203-5154", "phone": "5184640279"}, "mail-address": {"street1": "21 CORPORATE CIRCLE", "street2": "P O BOX 15098", "city": "ALBANY", "state": "NY", "zip": "12203-5154"}}
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 10, 2012
ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in
Charter)
Delaware
000-25323
14-1742717
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
21 Corporate Circle, P.O. Box 15098, Albany, NY
12212
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code:
(518) 512-2000
(Former name or former address, if
changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below) :
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 12, 2012,
Albany Molecular Research, Inc. (the "
Company
") issued a press release (the "
Press Release
")
announcing that Mr. Michael Nolan has been appointed by the Board of Directors as the Vice President, Chief Financial Officer and
Treasurer of the Company, such appointment to be effective on September 17, 2012.  Mr. Nolan will enter into an Employment
Agreement with the Company effective September 17, 2012 (the "
Employment Agreement
").
Mr. Nolan, 46, was most recently Vice President
Finance, Financial Planning and Analysis at the Delaware North Companies, headquartered in Buffalo, New York. Prior to that, Mr.
Nolan spent three years, from 2009 through 2012, at Thermo Fisher Scientific, Inc. in the role of Vice President, Finance, Analytical
Instruments Group where he was responsible for the global financial operations of a portfolio with revenue of $3 billion operating
across 3 divisions with 15 business units, 41 plant sites and 9,700 employees. Prior to Thermo Fisher Scientific, from 2004 through
2009, Mr. Nolan held positions of increasing responsibility at ALCAN, which was later acquired by Rio Tinto plc. Most recently,
while at Rio Tinto plc, Mr. Nolan was accountable for leading the integration of 13 global ALCAN and Rio Tinto plc functions, including
legal, company secretarial, business development and all finance functions including both the corporate and business teams. Mr.
Nolan began his career in 1989 at E.I. du Pont de Nemours Company and received his MBA from The University of Windsor and a B.A.
in Economics from The University of Western Ontario.
Mr. Nolan will report
to the Chairman, President and Chief Executive Officer of AMRI. Mr. Nolan will receive a base salary of $370,000 per year and is
eligible for a cash bonus of up to 67.5% of his base salary, which would be paid with respect to any fiscal year based on the performance
of the Company to established objectives, along with the achievement of personal goals set for Mr. Nolan. In addition, Mr. Nolan
will be paid a signing bonus of approximately $31,000 at the time of employment and will be eligible for the Company's standard
relocation package for senior executive officers. In the event that Mr. Nolan terminates his employment with AMRI within 24 months
he will be required to repay the signing bonus and any relocation fees actually incurred. Effective on the date of employment Mr.
Nolan will be granted non-qualified stock options to purchase 100,000 shares of the Company's common stock and 50,000 shares
of restricted stock. The stock options will be granted at the fair market value on the date of grant and the shares of restricted
stock and the stock options will vest 25% per year on each anniversary of the date of grant. The Employment Agreement is expected
to contain terms and conditions regarding restrictive covenants; termination; change of control; and other matters similar to those
found in the employment agreements currently in place between the Company and its other senior executive officers.
The Press Release also
announced that Mr. Mark T. Frost, the Senior Vice President of Finance and Administration, Chief Financial Officer and Treasurer
of the Company, will be terminating employment with the Company on September 14, 2012.  Mr. Frost has entered into a
Separation Agreement with the Company effective September 10, 2012 (the "
Separation Agreement
"), which provides
that Mr. Frost's last day of employment with the Company will be September 14, 2012 (the "
Termination Date
").
The Separation Agreement
provides for the payment of certain severance benefits to Mr. Frost following the Termination Date and the continuation of certain
obligations under the terms of the Amended and Restated Employment Agreement between the Company and Mr. Frost dated as of April
5, 2012.  The severance benefits include the following: (a) base salary and health and dental benefit continuation through
December 31, 2013; (b) certain bonus payments related to the Company's fiscal 2012 year, which will be payable only after
the completion of the fiscal year and a portion of which is dependent on the Company meeting its performance goals for such fiscal
year, (c) payment of certain outplacement expenses and (d) vesting of certain outstanding restricted stock awards held by Mr. Frost
immediately prior to the Termination Date that vest over time and have not vested.  Mr. Frost will receive his regular
rate of salary through the Termination Date.  In addition, the Separation Agreement includes a mutual general release
of claims between Mr. Frost and the Company arising out of or related to Mr. Frost's employment with the Company.
The description of
the Separation Agreement and the Employment Agreement contained herein do not purport to be complete and are qualified in the entirety
by reference to the complete text of the Separation Agreement and the Employment Agreement.
A copy of the press release announcing these
events is attached hereto as Exhibit 99.1 and is furnished herewith.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated September 12, 2012.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 13, 2012
ALBANY MOLECULAR RESEARCH, INC.
By:
/s/ Lori M. Henderson
Name: Lori M. Henderson
Title:  Vice President and General Counsel
EXHIBIT INDEX
Exhibit
No.
Description
99.1
Press Release dated September 12, 2012.